Skip to main content
. 2017 Jul 12;166(1):217–226. doi: 10.1007/s10549-017-4388-0

Table 3.

Combined analysis including all the sample sets (Helsinki, Tampere, Kuopio, and Oulu) in different subgroups, with the number of the FANCM c.5101C>T and c.5791C>T mutation carriers (combined) and non-carriers

Study cohort OR P 95% CI N Helsinki wt/mut N Tampere wt/mut N Oulu wt/mut N Kuopio wt/mut N Helsinki controls wt/mut N Tampere controls wt/mut N Oulu controls wt/mut N Kuopio controls wt/mut
All BC 1.86 0.0002 1.32–2.49 2285/81 656/35 1293/30 419/11 1234/21 782/21 498/12 157/1
Familial BC 1.99 0.004 1.24–3.19 1020/38 148/5
Unselected BC 1.77 0.0006 1.28–2.45 1652/58 656/35 1124/23 419/11
ER+ 1.64 0.005 1.17–2.32 1721/55 480/22 426/8 292/8
ER- 2.02 0.004 1.25–3.25 405/16 114/8 108/1 99/2
TNBC 3.08 0.00007 1.77–5.35 130/10 60/5 68/1 58/2

BC breast cancer, ER estrogen receptor, TNBC triple-negative breast cancer, wt wild type, mut mutation carrier